PY
Pyxis Oncology, Inc.
PYXS · NASDAQ
$2.90 -1.36% (-$0.04)
1M -10.49%
Market Cap $202.1M
P/E Ratio -
Div. Yield -
ROE 215.23%
Bulios Fair Price
$2.62
9.7% downside
Current Price
$2.9
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PYXS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 17.67x
P/S 18.31x
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 30.75%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Net margin 803.83%
Op. margin 834.45%
FCF margin 615.32%
Quality
3 /100
Poor ROE 215.23%
ROA 161.55%
Asset turnover 0.20x
Debt
42 /100
Moderate Current ratio 1.34x
Debt/Equity 1.56x
Net debt/EBITDA N/A
Stability
53 /100
Moderate EPS volatility 22.64%
Profitable years 0
Beta 1.34x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PYXS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Thomas Civik
Employees
56
Headquarters
Boston
Upcoming events
02 NOV
Earnings
Upcoming earnings report